Jefferies Upgrades Questcor Pharmaceuticals (QCOR) to Buy, Sees Little Downside and Improved Visibility
Get Alerts QCOR Hot Sheet
Price: $93.60 --0%
Rating Summary:
5 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 11
Rating Summary:
5 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 11
Join SI Premium – FREE
Jefferies upgraded Questcor Pharmaceuticals (NASDAQ: QCOR) from Hold to Buy with a price target of $28.00 (from $24.00), citing limited downside and improved visibility.
"We are upgrading QCOR to Buy from Hold given limited downside and improved visibility," analyst Biren Amin said. "We believe current valuation implies loss of MS and NS payer coverage. Our channel-checks with payers at AMCP suggest NS may be less at risk on lower Rx with improved cost-effectiveness via pot'l efficacybased measure and insurer rebates. Our new $28 PT assumes loss of MS sales, moderating NS growth, insurer rebates and a legal reserve."
For an analyst ratings summary and ratings history on Questcor Pharmaceuticals click here. For more ratings news on Questcor Pharmaceuticals click here.
Shares of Questcor Pharmaceuticals closed at $20.29 yesterday.
"We are upgrading QCOR to Buy from Hold given limited downside and improved visibility," analyst Biren Amin said. "We believe current valuation implies loss of MS and NS payer coverage. Our channel-checks with payers at AMCP suggest NS may be less at risk on lower Rx with improved cost-effectiveness via pot'l efficacybased measure and insurer rebates. Our new $28 PT assumes loss of MS sales, moderating NS growth, insurer rebates and a legal reserve."
For an analyst ratings summary and ratings history on Questcor Pharmaceuticals click here. For more ratings news on Questcor Pharmaceuticals click here.
Shares of Questcor Pharmaceuticals closed at $20.29 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA Securities Upgrades Estee Lauder (EL) to Buy; 'Earnings have bottomed'
- Safran SA (SAF:FP) (SAFRY) PT Raised to EUR211 at Citi, 'remain positive on the aftermarket'
- Home Depot (HD) PT Raised to $360 at Telsey, 'in the long term, Home Depot should remain a winner in retail'
Create E-mail Alert Related Categories
Analyst PT Change, Hot Upgrades, Trader Talk, UpgradesRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!